Intraoperative lymphatic mapping and sentinel lymphadenectomy for patients with breast cancer were introduced by Giuliano 1 at the 1993 meeting of the American Surgical Association. Before this, level I and II axillary lymph node dissection with a single-section H&E stain of each axillary node in the surgical specimen was the most reliable method for determination of the tumor status of this regional nodal basin. 2 Many studies have confirmed that when performed at centers with an experienced team of surgeons, pathologists, and nuclear medicine physicians, lymphatic mapping and sentinel lymphadenectomy are more accurate than axillary lymph node dissection for determining the histopathologic tumor status of the axilla in patients with breast cancer. [3] [4] [5] [6] [7] At these experienced centers, lymphatic mapping and sentinel lymphadenectomy are replacing axillary lymph node dissection as the axillary procedure of choice for patients with breast cancer. As lymphatic mapping and sentinel lymphadenectomy for breast cancer have become more prevalent, the technical aspects of the surgical procedure have been refined. However, there is no standard method for handling and histopathologic examination of the sentinel node (SN) ❚Table 1❚.
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Standard pathologic evaluation of a lymph node entails bisecting the node and examining each face with H&E staining. In 1948, Saphir and Amromin 26 first suggested that this single-section H&E examination of axillary nodes, which examines only a small portion of each node, is inadequate for reliable detection of axillary metastases in patients with breast cancer. By examining serial sections of axillary nodes, they detected metastases in 33% of axillary lymph node dissection specimens originally determined to be tumor-free by singlesection H&E. Many investigators have since shown that when serial sectioning is performed, the axillary metastasis detection rate is increased by 7% to 33%. 27 More recently, cytokeratin immunohistochemical staining has been introduced as a means of increasing the tumor detection rate in axillary nodes. Numerous studies have demonstrated an increased tumor detection rate, ranging from 14% to 17%, when immunohistochemical staining is added to routine H&E evaluation of axillary nodes. 27 Unfortunately, serial sectioning and immunohistochemical examination of all axillary nodes is too costly and labor-intensive for routine use.
However, in the era of lymphatic mapping and sentinel lymphadenectomy, where only 1 or 2 SNs are harvested in 10 Divided into 5 segments 5 ----Turner et al (1997) 5 Bisected if >4 mm 2 2 MAK-6 2 -Veronesi et al (1997) 11 Bisected if >0.5cm, sectioned 3 --None or 3+ -100-500 µm apart or bisected, half frozen, half permanent Barnwell et al (1998) 12 Bisected 2 ----Dale and Williams (1998) 13 Not stated 2 ----DeCicco et al (1998) 14 Bisected longitudinally if >0.5cm, 3 ----sectioned at 0.3-to 1-mm intervals Jannink et al (1998) 15 Bivalved then sectioned at 0. 25 Bisected if >8mm; multiple sections 3-5 1 AE1/3 --if >1 cm, then 3 additional sections at 100 µm, 100 µm, and 200 µm depths the majority of patients, the pathologist can focus time and resources on a thorough evaluation of the SN specimen. Giuliano et al 8 demonstrated that serial sectioning and immunohistochemical examination of the SN specimen increased the detection rate of lymph node metastases from 29.1% to 42.0% (P < .03) compared with axillary lymph node dissection with routine H&E examination of all axillary nodes. Several studies have shown that adding serial sectioning and immunohistochemical staining to the histopathologic workup of the SN significantly increases the metastatic tumor detection rate compared with routine H&E examination. 15, [20] [21] [22] 25, 28 Early critics of lymphatic mapping and sentinel lymphadenectomy questioned whether the increased rate of tumor detection demonstrated with the technique was due to the more intensive histopathologic evaluation of the SN, rather than the true biologic significance of the SN.
Only 2 published studies have attempted to address this question with complete histopathologic examination of each non-SN in a manner similar to the SN. Turner and colleagues, 29 in a single institution study, demonstrated that despite additional sections with immunohistochemical staining of all non-SNs, the SN remained the node most likely to contain a metastasis. Similarly, Weaver et al, 25 in a limited multi-institutional trial, demonstrated that an SN is much more likely to contain a metastasis than a non-SN, even after thorough examination of all axillary nodes with serial H&E-and immunohistochemically stained sections. Together, these trials suggest that the SN has true biologic significance as the node most likely to harbor metastatic disease.
We believe the SN contains important histopathologic information regarding the biology of a patient's breast cancer. Consequently, we believe the handling, processing, and pathologic examination of the SN is critical for accurate detection of metastatic disease. During our institutional validation trial, we hypothesized that a focused histopathologic examination of all SNs and non-SNs with serial sectioning and immunohistochemical staining would confirm the SN as the axillary node most likely to harbor metastatic tumor.
Materials and Methods

Patient Selection
Patients with clinical T1 or T2 N0 M0 breast cancer 30 were eligible for the study. The protocol was approved by the University of North Carolina Institutional Review Board, and informed consent was obtained from all participants. Each patient underwent attempted lymphatic mapping and sentinel lymphadenectomy followed immediately by standard level I and II axillary lymph node dissection.
Surgical Methods
Five surgeons (including B.F.C. and D.W.O.) participated in the study. Their lymphatic mapping and sentinel lymphadenectomy experience varied. One surgeon was trained formally in lymphatic mapping and sentinel lymphadenectomy for both breast cancer and melanoma during a Society of Surgical Oncology-approved fellowship. Three others had experience with lymphatic mapping and sentinel lymphadenectomy for melanoma. The final surgeon who participated in the study did not have experience with lymphatic mapping and sentinel lymphadenectomy but learned the technique under the guidance of the other surgeons throughout the validation trial.
Techniques for lymphatic mapping and sentinel lymphadenectomy combining both blue dye and technetium 99m ( 99m Tc)-labeled sulfur colloid (Nicomed Amersham Canada, Oakville, Ontario) have been described previously. 4, 29 Patients with medial hemisphere tumors underwent combined blue dye and 99m Tc-labeled sulfur colloid lymphatic mapping and sentinel lymphadenectomy. For patients with lateral hemisphere lesions, lymphatic mapping and sentinel lymphadenectomy were performed using either blue dye alone or the combination of blue dye and 99m Tc-labeled sulfur colloid, as determined by the operating surgeon.
The 99m Tc-labeled sulfur colloid was injected into the parenchyma adjacent to the primary tumor or into the wall of the biopsy cavity under sonographic guidance by a dedicated breast radiologist. If migration of the 99m Tc-labeled sulfur colloid was slow or absent, breast compression, warm compresses, and position modification were used to enhance migration. Still, in 2 of the first 10 patients, no migration of the 99m Tc-labeled sulfur colloid occurred. At that point in the study, the use of unfiltered 99m Tc-labeled sulfur colloid was discontinued, and all subsequent patients received filtered 99m Tc-labeled sulfur colloid, prepared in the following manner: (1) The radiopharmaceutical was filtered through a 0.22-µm Millex-GV filter unit (Millipore SA, Malsheim, France); (2) 250 µCi (9.25 MBq) of 99m Tc sulfur colloid were drawn up into each of four 3-mL syringes; (3) 0.9% sodium chloride was used to make a final volume of 2 mL in each syringe; (4) each syringe was affixed with a 25-gauge × 1.5-inch needle that was used for injection; (5) the filtered 99m Tc-labeled sulfur colloid was injected in the same manner as the unfiltered 99m Tc-labeled sulfur colloid described in the previous paragraph.
In the operating room, the breast tissue adjacent to the primary tumor or the wall of the biopsy cavity was injected with 3 to 5 mL of isosulfan blue dye (Lymphazurin, Hirsch Industries, Richmond, VA). The area then was compressed for 3 to 7 minutes. When the tumor was not palpable, the mammographer placed a localization needle, and 99m Tc-labeled sulfur colloid and blue dye were injected into the breast tissue adjacent to this localization needle.
Before skin incision, the area within the axilla with the greatest number of counts per second was located with a commercially available handheld gamma detection probe. A transverse axillary incision was made in this area. Careful dissection of the underlying tissue was performed until a blue-stained lymphatic channel was located. If the bluestained lymphatics were difficult to find or follow, the handheld probe was used to direct the dissection. Once identified, the blue lymphatic channel was tracked proximally and distally until a blue node was located. This node was labeled as the SN. The ex vivo SN activity and the residual background activity in the axilla then were documented. If the ratio of the ex vivo SN counts per second to the background counts per second remained greater than 10:1 after removal of the SN, the dissection was continued to identify and remove all additional SNs. Following lymphatic mapping and sentinel lymphadenectomy, all patients underwent modified radical mastectomy or lumpectomy with level I and II axillary lymph node dissection. If a previous successful lumpectomy had been performed, patients underwent only lymphatic mapping and sentinel lymphadenectomy followed by level I and II axillary lymph node dissection.
Histopathologic Examination of SNs and Non-SNs
At the initiation of our institutional validation trial, each SN, under the supervision of a surgical pathologist, was bisected and examined in the frozen section room for any obvious gross abnormalities. If any "suspicious" areas were found on gross inspection, this portion of the node was processed for histologic evaluation with H&E stain. If no suspicious gross abnormalities were detected, one half of the SN was processed by surgical pathology for histologic evaluation, and the other half was cryopreserved and sent for future studies to the University of North Carolina Lineberger Comprehensive Cancer Center Tissue Procurement and Analysis Core Facility ❚Figure 1❚. Approximately halfway through the study, non-SN metastases were identified in the axillary lymph node dissection specimens from 2 cases with tumor-free SNs. The frozen SN tissue from these 2 cases was retrieved from the tissue procurement facility, and subsequent H&E examination of this additional tissue revealed an SN metastasis in both cases. From this point forth, gross handling of the SN was changed.
The new protocol called for manual sectioning of the entire SN into slices 1.0 mm or smaller. The SN was first bivalved along the shortest axis. Each half then was rotated so that the cut surface faced up. The halves were placed adjacent to each other, and the node then was cut into 1-mm slices parallel to the cut surface. Alternating slices were sent to surgical pathology and the tissue procurement facility. The majority of nodes yielded two 1-mm-thick slices for surgical pathology ❚Figure 2❚. The intent of the new protocol was to maximize our ability to detect micrometastatic disease while also saving tissue for future studies. Tissue procurement Surgical pathology ❚Figure 1❚ Originally, each sentinel node was (1) bisected and examined in the frozen section room. If no "suspicious" gross abnormalities were detected, (2) one half was cryopreserved and sent to the University of North Carolina Lineberger Comprehensive Cancer Center Tissue Procurement and Analysis Core Facility and (3) the other half was processed in surgical pathology for histologic evaluation.
❚Figure 2❚ Under the revised protocol, each sentinel node (SN) was still (1) bisected and examined in the frozen section room. However, each half of the SN then was (2) rotated 90 degrees so the cut surface faced up and then (3) manually sectioned parallel to the cut surface into slices 1.0 mm or smaller. Alternating slices were sent to the (4) tissue procurement facility and to (5) surgical pathology.
The tissue submitted to surgical pathology was fixed in formalin, processed overnight, and embedded in paraffin. Before the change in handling, initial evaluation of each SN was performed by examination of a single H&E-stained slide from the cut face of the bivalved node. After the change in protocol, initial evaluation of each SN entailed examination of a single H&E-stained slide from each 1-mm SN slice. If a metastasis was discovered during the initial H&E examination, no further sections were obtained from the SN.
For patients whose SN was tumor-free on this initial H&E examination, additional levels were obtained. Again, before the change in handling, 4 levels, separated by 15 to 20 µm, were obtained from the cut face of the node. Levels 
Immunohistochemical staining was performed using a standard avidin-biotin technique. An immunohistochemically stained node was considered to contain metastasis if the cytokeratin-positive cells were cytologically malignant or if they were arranged in such a way that the architecture was concordant with the primary tumor. For cases with more than 1 SN, all tumor-free SNs on initial H&E examination underwent additional sectioning and staining as described in the previous paragraph.
Non-SN tissue was not submitted to the tissue procurement facility. All non-SNs were processed by surgical pathology, fixed in formalin, processed overnight, and embedded in paraffin. A minimum of 1 H&E-stained slide was examined for every non-SN. If a node was large, it was bisected and put in 2 cassettes, yielding 2 H&E-stained slides. If a node was small, more than one 4-µm thick section often was present on the initial slide. The non-SNs from cases with a tumor-free SN underwent additional sectioning and staining in a manner identical to the SN. Four additional levels, separated by 15 to 20 µm, were obtained. Levels 1, 3, and 4 underwent H&E staining, while level 2 underwent immunohistochemical staining. All non-SNs from cases with a tumor-free SN were examined at a minimum of 1 immunohistochemical and 4 H&E stained sections ❚Table 2❚.
The size of the largest SN metastasis was recorded. A micrometastasis was defined as a metastasis of 2.0 mm or less. An ocular micrometer was used to determine the size of micrometastases to the nearest 0.01 mm.
Statistical Methods
The McNemar test was used to compare the rate of metastasis in non-SNs from cases with a tumor-free SN with the rate of metastasis in SNs. This test was performed at an alpha = .05 significance level.
Results
From July 1998 through August 1999, 78 patients (75 women, 3 men) with primary breast carcinoma and no palpable adenopathy were enrolled in the study. Two women had bilateral synchronous primary tumors, resulting in a total of 80 cases. In 4 cases, lymphatic mapping and sentinel lymphadenectomy were not successful. In 2 of these cases, there was no migration of the unfiltered 99m Tc-labeled sulfur colloid during lymphatic mapping, and no sentinel lymphadenectomy was attempted. In a third case, there was no migration of the filtered 99m Tc-labeled sulfur colloid during lymphatic mapping. Sentinel lymphadenectomy using blue dye was attempted in this patient; however, no SN was located. This patient had extensive axillary tumor involvement on subsequent axillary lymph node dissection (10/10 tumor-involved nodes), which was thought to have contributed to the failure of 99m Tc-labeled sulfur colloid and blue dye migration. In the fourth case, there was adequate migration of 99m Tc-labeled sulfur colloid during lymphatic mapping; however, no SN was located during dissection despite use of both 99m Tc-labeled sulfur colloid and blue dye. For the entire group, the SN was located in 76 of 80 cases, resulting in an overall SN identification rate of 95%. The SN was identified in 76 of 78 cases in which sentinel lymphadenectomy was attempted, for an SN identification rate of 97%.
The mean age of the 74 patients who underwent successful lymphatic mapping and sentinel lymphadenectomy was 55. (Table 2) . In 21 (28%) of 76 cases, an SN metastasis was detected by initial H&E examination. Additional H&E sections revealed an occult metastasis in 2 (4%) of 55 cases in which the SN was shown as tumor-free by initial H&E evaluation. Subsequent examination with immunohistochemical staining identified metastases in 5 additional cases (9%). Four of the immunohistochemically detected metastases consisted of cytologically malignant, cytokeratin-positive cells in the subcapsular sinus. In the fifth case, a cluster of cytokeratin-positive cells was identified within the parenchyma of the node. Review of the original H&E-stained sections by the study pathologist (M.V.I.) confirmed the absence of H&E-detectable micrometastatic disease. Overall, 7 (13%) of 55 diagnoses were converted from tumor-negative to tumor-positive by serial sections and immunohistochemical examination. All (100%) of the previously occult metastases were micrometastases (2.0 mm or smaller).
In 48 (63%) of 76 cases, no tumor was identified in the SN despite additional sectioning and staining with H&E and an immunohistochemical stain. A total of 724 non-SNs were removed during these 48 cases. Initial H&E examination did not reveal metastasis in any of these 724 non-SNs. As a result, the false-negative rate, based on standard singlesection H&E examination, was zero. All 724 tumor-free non-SNs then were subjected to additional sectioning and staining with H&E and an immunohistochemical stain. Each non-SN underwent the same intensive examination as the SN. A minimum of 5 slides (4 H&E, 1 immunohistochemical stain) were examined for each individual non-SN. In total, 1,647 H&E-stained non-SN slides and 378 immunohistochemically stained non-SN slides were examined. No occult metastases were identified in any of the 724 non-SNs. After additional sectioning and staining with H&E and an immunohistochemical stain, the false-negative rate remained zero.
In summary, while occult metastases were identified in 7 (13%) of 55 cases in which the SN was shown as tumorfree by initial H&E, the same thorough examination did not reveal occult metastases in any of the 724 non-SNs from these 55 cases (P < .05). Overall, while 28 (37%) of 76 cases had SN metastases detected by H&E and/or immunohistochemical examination, none of the 48 cases with tumor-free SNs demonstrated a non-SN metastasis on H&E or immunohistochemical examination. The SN false-negative rate for this institutional validation trial after additional sectioning and staining of all SNs and non-SNs with H&E and an immunohistochemical stain was zero.
Discussion
Since Giuliano's 1 initial description of lymphatic mapping and sentinel lymphadenectomy in patients with breast cancer, it has become evident that when performed at institutions with an experienced team of surgeons, pathologists, and nuclear medicine physicians, the technique is a reliable and accurate method for detecting axillary nodal metastases in breast cancer patients. [3] [4] [5] [6] [7] By allowing the pathologist to focus attention on a few nodes, lymphatic mapping and sentinel lymphadenectomy have increased the metastatic tumor detection rate for breast cancer, making lymphatic mapping and sentinel lymphadenectomy more accurate than routine level I and II axillary lymph node dissection. 8, 15, [20] [21] [22] 25, 28 
Histopathologic Validation of the SN Hypothesis
Early critics of lymphatic mapping and sentinel lymphadenectomy suggested that the increased metastatic tumor detection rate was the result of intensive histopathologic examination of the SN rather than the true biologic significance of the SN. Turner et al 29 addressed this issue in a study of 103 patients with breast cancer undergoing lymphatic mapping and sentinel lymphadenectomy and completion axillary lymph node dissection. For patients whose SN was tumor-free on H&E examination, they further examined all SNs and non-SNs with a cytokeratin antibody cocktail (MAK-6, Ciba-Corning, Alameda, CA). Immunohistochemical examination identified previously occult micrometastatic disease in 10 (14%) of 70 cases. In contrast, immunohistochemical examination of the non-SNs from the same patients revealed only 1 case (1%) with occult micrometastatic disease (P < .0001). This single institutional study confirms that the SN has biologic significance and that increased metastatic tumor detection is not simply a function of more intensive and sophisticated histopathologic techniques.
In a multi-institutional SN validation trial, Weaver et al 25 identified SN metastases by routine H&E examination in 104 (27.0%) of 385 cases and non-SN metastases by routine H&E examination in 57 (14.8%) of 385 cases. They then performed retrospective serial sectioning and immunohistochemical examination with cytokeratin stains AE1-3 (Boehringer-Mannheim, Indianapolis, IN) of all tumor-free SNs and non-SNs. Workup of the cases with an SN negative by routine H&E examination identified occult SN metastases in 19 (8.9%) of 214 cases. In contrast, occult metastases were identified in only 7 (3.3%) of 214 non-SNs. The increased detection of metastatic tumor in the SN compared with the non-SN by both routine methods and serial sectioning with immunohistochemical examination validates the SN hypothesis.
To validate lymphatic mapping and sentinel lymphadenectomy for patients with breast cancer at our institution and to confirm the biologic significance of the SN, we examined both SNs and non-SNs with similar histopathologic techniques. We performed additional sectioning and immunohistochemical staining of both the tumor-free SN and the tumor-free non-SNs. For the 55 cases with H&E-negative SNs, serial sectioning and immunohistochemical examination of tumor-free nodes revealed previously occult metastases in 7 (13%) of 55 SN specimens (2 metastases identified by H&E examination; 5 metastases identified by immunohistochemical analysis) and none of the non-SNs (P < .05). Thus, despite examining 4,100 H&E-stained non-SN levels and 866 immunohistochemically stained non-SN levels, the SN still was significantly more likely to contain metastasis than the non-SN, validating the SN hypothesis for breast cancer at our institution and confirming the biologic significance of the SN.
Handling and Processing of the SN
One technical issue that arose during this institutional validation trial involved the handling and processing of the SN. Approximately halfway through the study, 2 patients were found to have non-SN metastases, despite having SNs that were tumor-free by both H&E and immunohistochemical examination. By our initial protocol, one half of each bisected SN had been retained by surgical pathology, while the other half had been sent to the tissue procurement facility and preserved for future studies. In both cases, when the frozen tissue was retrieved from the tissue procurement facility and examined, an SN metastasis was identified. While preserving SN tissue for future studies is important, it cannot take precedence over obtaining an accurate assessment of the histopathologic tumor status of the axilla. One study estimated a 10% misclassification rate of node-positive cases as node-negative when only one half of each bisected node from axillary lymph node dissection specimens was examined. 31 Failing to detect an SN metastasis in 10% of cases with axillary tumor involvement would be unacceptable. For example, premenopausal patients with a T1a or T1b breast cancer and a tumor-free SN would not be recommended to receive systemic adjuvant therapy. However, if the SN contained metastatic tumor, a doxorubicin-based chemotherapy regimen would be seriously considered. Misclassification would thus lead to a major difference in the postoperative systemic treatment recommendations.
Realizing that examination of only one half of each bisected SN was inadequate, we changed the protocol for handling the SN. The new protocol called for alternating slices of the SN, each 1.0 mm or smaller, to be submitted to surgical pathology and to the tissue procurement facility. After implementation of the new protocol, no non-SN metastases were identified in cases with a tumor-free SN. By submitting alternating slices of the whole SN rather than the entirety of half the SN to surgical pathology, we were able to minimize the risk of failing to detect a micrometastasis owing to lost tissue, while still preserving tissue for future studies.
Histopathologic Examination of the SN
Currently, standard histopathologic evaluation of a lymph node involves single-section H&E examination. Many studies have shown that serial sectioning and immunohistochemical examination enhance metastatic tumor detection in axillary lymph node dissection specimens. 27 More recently, several studies have demonstrated a significantly increased metastatic tumor detection rate with the addition of these techniques to the SN workup. 8, 15, [20] [21] [22] 25, 28 The present study demonstrated an increase in the metastatic tumor detection rate from 28% (21/76) to 37% (28/76) with the addition of serial sectioning and immunohistochemical examination of the SN.
While all groups perform standard single-section H&E examination of the SN, most have expanded the histopathologic workup in an effort to enhance metastatic tumor detection. Frozen sections, serial sectioning, and immunohistochemical staining all have been incorporated into the examination of the SN. Even among institutions using these techniques, the methods vary widely (Table 1) . Serial sectioning has no consensus definition; the number and interval of sections vary considerably. Similarly, immunohistochemical techniques differ in the number of sections examined and the stains used. If lymphatic mapping and sentinel lymphadenectomy are to be implemented widely, a consensus on the standard histopathologic evaluation of the SN needs to be defined.
Clinical Significance of Micrometastases
Both the change in handling and the addition of serial sections and immunohistochemical staining to the SN workup served to increase the rate of detection of micrometastases at our institution. While these techniques allowed more accurate staging of patients with breast cancer, the clinical implications of these nodal micrometastases are currently unknown. In 1981, Rosen et al 32 first demonstrated that patients with T1 primary tumors and micrometastases had a significantly diminished disease-free and overall survival at 10 years compared with patients with T1 primary tumors and no metastases. Meanwhile, a large 1982 study by Wilkinson et al 33 failed to show any survival difference between patients with micrometastases and patients with no metastatic tumor involvement. Several subsequent studies, including the 1990 Ludwig Breast Cancer Study Group, 34, 35 have demonstrated diminished disease-free and overall survival for premenopausal patients with micrometastases compared with patients with no metastatic tumor involvement. 27 Ultimately, retrospective studies have been inconclusive regarding the clinical implications of occult micrometastatic disease detected by cytokeratin immunohistochemical stains. Furthermore, all of these retrospective studies predate the SN era. In these studies, the lymph node was bisected and evaluated with a single H&E-stained section. Today, in the SN era, the node is evaluated prospectively with multiple levels of H&E stain. If a micrometastasis is detected by H&E stain in any of these levels, most clinicians are willing to treat the patient as a node-positive breast cancer patient. In contrast, neither surgeons nor medical oncologists know what to do with patients who have micrometastases detected only by immunohistochemical cytokeratin staining. The natural history of immunohistochemically detected micrometastases remains unknown. Currently, the American College of Surgeons Oncology Group (ACOSOG) and the National Surgical Adjuvant Breast Project (NSABP) are evaluating prospectively the clinical significance of occult micrometastatic disease detected by immunohistochemical analysis in an attempt to resolve this very important clinical issue (ACOSOG Z0010, A prognostic study of sentinel node and bone marrow micrometastases in women with clinical T1 or T2 N0 M0 breast cancer, Armando E. Giuliano, MD, principal investigator, and NSABP B32, A randomized phase III clinical trial to compare sentinel node resection to conventional axillary dissection in clinically node-negative breast cancer patients, David Krag, MD, principal investigator). Until the results of these studies are known, most clinicians would prefer not to have the information offered by cytokeratin immunohistochemical staining.
Summary
With an SN identification rate of 95% and a false-negative rate of zero, even after serial sectioning and immunohistochemical examination of all tumor-free nodes, this study histopathologically validates the SN hypothesis at our institution using these techniques. We believe that the SN has true biologic significance as the axillary node most likely to harbor metastatic tumor. Consequently, we have transitioned to lymphatic mapping and sentinel lymphadenectomy as the axillary staging procedure of choice for patients with clinical T1 or T2 N0 M0 breast cancer at our institution.
Similarly, moves toward integration of lymphatic mapping and sentinel lymphadenectomy into routine care of patients with breast cancer are underway at many other institutions. While surgeons trained in lymphatic mapping and sentinel lymphadenectomy for breast cancer during Society of Surgical Oncology-approved fellowships are able to accurately perform the procedure independently after fellowship, 36 widespread implementation of the technique will require training of practicing physicians at both academic medical centers and community hospitals. Such training will require standardization of the techniques of lymphatic mapping and sentinel lymphadenectomy. Many of the surgical aspects of the procedure have been refined; however, processing, handling, and histopathologic evaluation of the SN varies considerably from institution to institution. Continued evolution toward a standardized technique in nuclear medicine, surgery, and pathology is crucial for disseminating the techniques of lymphatic mapping and sentinel lymphadenectomy for patients with breast cancer to the community while still maintaining the high degree of accuracy seen in experienced institutions.
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